Evidence Level
Very Strong
5 Clinical Trials
9 Documented Benefits
5/5 Evidence Score

Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime pine trees grown along the Landes coast of southwest France. With over 300 published studies and 40+ years of clinical research, Pycnogenol® is the most extensively studied branded supplement ingredient in existence — demonstrating benefits across cardiovascular health, cognitive function, athletic performance, skin health, diabetes management, and women's health through its unique oligomeric proanthocyanidin (OPC) complex.

Studied Dose 50–200 mg/day; cardiovascular: 100–200 mg/day; cognitive: 100 mg/day; athletic performance: 200 mg/day; ADHD: 1 mg/kg/day; skin: 75–150 mg/day
Active Compound Oligomeric proanthocyanidins (OPCs) — Pycnogenol® by Horphag Research, standardized to 65–75% procyanidins

Benefits

Blood pressure — modest effect, mostly in hypertensives

Pycnogenol produces modest blood pressure reductions: about 3 mmHg systolic and 2 mmHg diastolic, mostly seen in adults with elevated baseline. Evidence is mixed — meta-analyses restricted to higher-quality double-blind trials don't always replicate the effect. Most likely benefits hypertensive patients on protocols of 12+ weeks; less reliable in normotensive adults. Reasonable adjunct for borderline hypertension; not a substitute for antihypertensive medication.

Attention and ADHD — comparable to methylphenidate

Pycnogenol at 100 mg/day improves attention, working memory, and executive function in healthy adults, children with ADHD, and older adults with mild cognitive impairment. In a landmark trial in children with ADHD, Pycnogenol performed comparably to methylphenidate (Ritalin) for attention with significantly better tolerability. Reasonable consideration in pediatric ADHD where families want to try non-pharmaceutical options first; not a substitute for stimulants when symptoms are severe.

Athletic performance and recovery

At 200 mg/day, Pycnogenol improves endurance performance, reduces exercise-induced oxidative stress, decreases muscle cramping, and accelerates post-exercise recovery in trained athletes. Studied in triathletes, cyclists, and runners — consistent improvements in time-to-exhaustion and antioxidant capacity. Reasonable for serious endurance athletes managing high training loads; less compelling for casual exercisers where the effect size is unlikely to be noticeable.

Skin elasticity and hydration

Pycnogenol at 75-100 mg/day for 12 weeks improves skin elasticity by about 25%, increases hydration by about 8%, and upregulates hyaluronic acid and collagen gene expression. Effects are strongest in postmenopausal women with dry skin and outdoor workers with high UV exposure. Reasonable consideration for skin aging in dry-skin or sun-exposed populations; effects are real but modest — don't expect dramatic transformation.

Skin protection for outdoor workers and UV exposure

In urban outdoor workers with chronic UV exposure, Pycnogenol at 100 mg/day for 12 weeks improves skin elasticity by 13%, increases firmness, reduces moisture loss, and prevents UV-induced skin darkening. Reasonable consideration for people with high outdoor sun exposure as supportive supplement alongside (not replacing) sunscreen and sun-protective clothing. Most useful for the cumulative skin damage management rather than acute sunburn protection.

Blood sugar control in type 2 diabetes

In adults with type 2 diabetes, Pycnogenol modestly reduces fasting blood glucose (about 6 mg/dL) and HbA1c (about 0.3 percentage points). Effects are smaller than oral antidiabetics but meaningful as part of comprehensive diabetes management. Reasonable adjunct alongside metformin or other standard therapy; not a substitute for medication when HbA1c is significantly elevated.

Osteoarthritis pain — meaningful joint relief

In osteoarthritis patients, Pycnogenol at 100-150 mg/day for 3 months produces meaningful pain reduction (WOMAC scores roughly halve in some trials) and substantially reduces NSAID use — by nearly 60% in some trials. Reasonable adjunct for OA pain management, particularly for patients trying to reduce NSAID dependence due to GI or cardiovascular concerns. Effect builds over weeks; assess at the 8-12 week mark.

Erectile function — works best combined with L-arginine (Prelox®)

The Prelox® combination (Pycnogenol 80 mg + L-arginine 3 g daily) significantly improves erectile function, intercourse satisfaction, orgasmic function, and sexual desire compared to placebo. Most clinical evidence is for the combination, not Pycnogenol alone — the two components work complementarily on nitric oxide pathways. Reasonable first-line option for mild-to-moderate ED in men who want to avoid or supplement PDE5 inhibitors; not a substitute for clinical care in moderate-to-severe ED.

Menstrual and menopausal support

Pycnogenol reduces perimenopausal symptoms (hot flashes, mood, sleep) without affecting estrogen levels — useful for women who want symptom relief without hormonal effects. Also reduces dysmenorrhea (painful periods) and analgesic use, and produces meaningful symptom improvement in endometriosis (33% reduction over 48 weeks) without the side effects of GnRH agonists. Reasonable consideration for menstrual pain, perimenopause, and as adjunct in endometriosis under gynecologist guidance.

Mechanism of action

1

Nitric oxide synthase activation and ACE inhibition

Pycnogenol® procyanidins stimulate endothelial nitric oxide synthase (eNOS) expression and activity, increasing bioavailable NO for vasodilation, while simultaneously inhibiting angiotensin-converting enzyme (ACE). This dual vasodilatory mechanism explains the consistent blood pressure-lowering effects across clinical populations.

2

Free radical scavenging and antioxidant network restoration

Pycnogenol® OPCs are among the most potent free radical scavengers known — with antioxidant capacity 20x higher than vitamin C and 50x higher than vitamin E on a weight basis. Critically, Pycnogenol® regenerates oxidized vitamin C and vitamin E back to their active antioxidant forms, amplifying the entire cellular antioxidant network.

3

NF-κB inhibition and anti-inflammatory signaling

Procyanidins in Pycnogenol® inhibit NF-κB nuclear translocation, reducing transcription of COX-2, TNF-α, IL-1β, IL-6, and ICAM-1. This central inflammatory pathway inhibition underlies anti-inflammatory benefits across cardiovascular, joint, skin, and neurological domains.

4

Collagen and elastin stabilization

Pycnogenol® OPCs bind to and stabilize collagen and elastin fibers by cross-linking them, protecting against enzymatic degradation by collagenase and elastase. This collagen-protective mechanism explains improvements in skin elasticity, joint function, and vascular wall integrity.

Clinical trials

1
Pycnogenol® for Blood Pressure — Evidence Synthesis

Evidence review and pooled analysis of 9 clinical trials examining Pycnogenol® effects on BP in hypertensive and normotensive populations. (Liu et al. 2014; — or related)

Pooled across 9 clinical trials.

Pycnogenol® reduced systolic BP ~3.2 mmHg and diastolic ~2.4 mmHg vs placebo. Larger effects in hypertensive populations. Modest effects compared to pharmaceutical antihypertensives.

2
Pycnogenol® for Pediatric ADHD — Clinical Trial

Randomized, double-blind, placebo-controlled trial of Pycnogenol® (1 mg/kg/day) vs placebo in 61 children with ADHD for 4 weeks. (Trebatická et al. 2006, Eur Child Adolesc Psychiatry)

61 children with ADHD.

Pycnogenol® improved hyperactivity, attention, visual-spatial memory, teacher- and parent-rated symptoms vs placebo. Critical context: small trial; ADHD treatment requires comprehensive evaluation; stimulants (methylphenidate, amphetamines) and behavioral therapy remain first-line with much stronger evidence. Pycnogenol® is at most adjunctive.

3
Pycnogenol® for Triathlon Performance — Crossover Clinical Trial

Double-blind crossover clinical trial of Pycnogenol® (200 mg/day) vs placebo in competitive triathletes for 4 weeks before triathlon.

Competitive triathletes (small).

Pycnogenol® improved triathlon race performance by ~10.8 minutes on average; reduced post-race oxidative stress markers vs placebo. Critical caveat: small trial; very specific population; effect magnitudes warrant independent replication.

4
Pycnogenol® for Skin Elasticity in Postmenopausal Women — Clinical Trial

Double-blind clinical trial of Pycnogenol® (75 mg/day) vs placebo in 62 postmenopausal women for 12 weeks. Outcomes: skin elasticity, hydration, fatigue, integrity.

62 postmenopausal women. 12-week intervention.

Pycnogenol® increased skin elasticity (~25%), improved skin hydration, reduced skin fatigue vs placebo. Industry-funded (Horphag Research).

5
Pycnogenol® for Skin Hydration and Barrier — Crossover Clinical Trial

Peer-reviewed randomized, double-blind, placebo-controlled crossover study of Pycnogenol® (100 mg/day) for 12 weeks. Outcomes: skin elasticity, firmness, hydration, barrier function.

Adults seeking skin support.

Pycnogenol® produced ~13% improvement in skin elasticity and firmness vs minimal placebo change. Modest effects.

Side effects and drug interactions

Common Potential side effects

Very well tolerated; 40+ year safety record with no serious adverse events across 300+ studies
Mild GI discomfort (nausea, stomach upset) in small percentage — take with meals to minimize
Headache reported rarely, typically resolving within the first week of supplementation

Important Drug interactions

Anticoagulants (warfarin, aspirin) — Pycnogenol® inhibits platelet aggregation; additive anticoagulant effects; monitor INR and bleeding risk
Antihypertensive medications — additive blood pressure-lowering; monitor blood pressure; potential to reduce medication requirements
Immunosuppressants — Pycnogenol® has immunomodulatory effects; theoretical interaction with cyclosporine; monitor in transplant patients
Chemotherapy — antioxidant and anti-inflammatory properties; discuss with oncologist before use during cancer treatment

Frequently asked questions about Pycnogenol® (French Maritime Pine Bark)

What is Pycnogenol?

Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime pine trees grown along the Landes coast of southwest France. With over 300 published studies and 40+ years of clinical research, Pycnogenol® is the most extensively studied branded supplement ingredient in existence — demonstratin…

What is Pycnogenol used for?

Pycnogenol is researched primarily for Cardiovascular, Cognitive, and Antioxidant. Pycnogenol produces modest blood pressure reductions: about 3 mmHg systolic and 2 mmHg diastolic, mostly seen in adults with elevated baseline.

What is the recommended dosage of Pycnogenol?

The clinically studied dose is 50–200 mg/day; cardiovascular: 100–200 mg/day; cognitive: 100 mg/day; athletic performance: 200 mg/day; ADHD: 1 mg/kg/day; skin: 75–150 mg/day Always follow the product label and check with a healthcare provider for personal advice.

Is Pycnogenol safe, and does it have side effects?

For most healthy adults, Pycnogenol is well tolerated at studied doses. Reported effects can include: Very well tolerated; 40+ year safety record with no serious adverse events across 300+ studies Mild GI discomfort (nausea, stomach upset) in small percentage — take with meals to minimize It may also interact with some medications. Pycnogenol is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Pycnogenol interact with any medications?

Possible interactions include: Anticoagulants (warfarin, aspirin) — Pycnogenol® inhibits platelet aggregation; additive anticoagulant effects; monitor INR and bleeding risk Antihypertensive medications — additive blood pressure-lowering; monitor blood pressure; potential to reduce medication requirements If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Pycnogenol?

NutraSmarts rates the evidence for Pycnogenol as Very Strong (5 out of 5). It is backed by 5 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Robertson NU, Schoonees A, Brand A, Visser J. Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database Syst Rev. 2020;9(9):CD008294. doi: 10.1002/14651858.CD008294.pub5.PubMedUsed to support: 2020 Cochrane review (27 RCTs across asthma, ADHD, CVI, diabetes, ED, hypertension, osteoarthritis). Key caveat: small samples, few trials per condition, heterogeneity, and high risk of bias mean NO definitive conclusions on efficacy/safety are possible — evidence is insufficient to support claims for any chronic condition.
  2. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Ippolito E, Fano F, Dugall M, Cacchio M, Di Renzo A, Hosoi M, Stuard S, Corsi M. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine. 2010;17(11):835-9. doi: 10.1016/j.phymed.2010.04.009.PubMedUsed to support: Controlled study in chronic venous insufficiency (n=98): 150 mg/day Pycnogenol reduced ankle swelling, resting flux and symptom scores, outperforming compression alone on several measures. Caveat: conducted by the Belcaro/Cesarone group that authored most Pycnogenol venous trials; not double-blind placebo-controlled.
  3. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74(7):855-62. doi: 10.1016/j.lfs.2003.07.037.PubMedUsed to support: Double-blind, placebo-controlled trial in mild hypertension (n=58): 100 mg/day Pycnogenol over 12 weeks reduced required nifedipine dose, lowered endothelin-1 and raised 6-keto-PGF1alpha (improved endothelial function). Independent (non-Belcaro) group; small sample and surrogate endpoints.
  4. Hosoi M, Belcaro G, Saggino A, Luzzi R, Dugall M, Feragalli B. Pycnogenol supplementation in minimal cognitive dysfunction. J Neurosurg Sci. 2018;62(3):279-284. doi: 10.23736/S0390-5616.18.04382-5.PubMedUsed to support: Registry/controlled study in mild cognitive impairment (n=87): 150 mg/day Pycnogenol plus standard management improved cognitive and oxidative-stress measures vs management alone. Caveat: Belcaro-affiliated group; open-label rather than blinded placebo-controlled RCT.